The Filing Desk

Surrozen

SRZN · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

SRZN · Last close · November 19, 2026
$30.67
Value Surrozen yourself

Surrozen's revenue fell 67.4% to $4 million in fiscal 2025. Its operating margin was −1,210.6%, down from −239.7% a year earlier. Free cash flow was −$30 million. The diluted share count rose 155.0%.

Surrozen, Inc./DE Latest fiscal year ended December 31, 2025 10-K filed March 23, 2026 · 0001193125-26-119818 Updated
Revenue
$4M
67.4%
Operating margin
−1,210.6%
970.9 pts
Net income
−$242M
 
Free cash flow
−$30M
 
Return on equity
—
 
Market cap
$362M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-14.9254), so every year is on today's share basis. The SEC's structured data gives diluted share counts for fiscal 2021 to 2025 in thousands without saying so; they are shown here in millions, which makes net income per share match the reported earnings per share. Return on equity for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Surrozen does

Surrozen is a biotechnology company in South San Francisco, California, that develops drugs aimed at the Wnt pathway, a signaling system the body uses to repair and maintain tissue. It has no approved products, so it has no product sales. Its current focus is eye disease. Its lead candidates are antibody-based drugs designed to mimic natural Wnt proteins and boost the pathway.

The company has two lead candidates for retinal diseases. SZN-8141 combines two actions: it activates a receptor called Frizzled 4 and blocks VEGF, a protein involved in abnormal blood vessel growth. It is being developed for diabetic macular edema and wet age-related macular degeneration, and the company expects to submit an application to begin human trials in the second half of 2026. SZN-8143 adds a block on interleukin-6 and is aimed at the same two diseases plus uveitic macular edema. Both have so far been tested in preclinical models. It also has research-stage programs for other eye diseases, including corneal endothelial disease.

Surrozen says it relies on third parties to run its preclinical studies and clinical trials. As of March 1, 2026, it had 44 full-time employees, 27 in research and development and 17 in general and administrative roles.

Its biggest risks, as it describes them

  • It has a history of losses and expects more, and may never become profitable.
  • It needs substantial additional funds to develop its drug candidates.
  • None of its candidates has regulatory approval, and human trials may not show they are safe and effective.
  • It may not succeed in using its Wnt platform to build a pipeline of drug candidates.
  • It relies on third parties to run its studies and trials, and trials are costly and can be delayed.
From Surrozen's annual report on Form 10-K, filed March 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Surrozen lost money in fiscal 2025: a net loss of $242 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments12476363589
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio7.8x8.3x5.8x5.3x9.2x
Quick ratio7.8x8.3x5.8x5.3x9.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Surrozen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Surrozen says to expect

  • Cash runway: funding of planned studiesThe Company anticipates its cash, cash equivalents and marketable securities to provide cash runway into 2029, including funding for completion of the expanded DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 5 insiders bought $6.9 million of Surrozen shares on the open market, and 4 insiders sold $7.2 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 22, 2026Chen-Ming Yu10% ownerSold325,000$21.25$6.9 millionForm 4
May 4, 2026Craig C ParkerChief Executive Officer, DirectorSold4,524$33.33$150,785Form 4
May 4, 2026Charles O WilliamsChief Operating OfficerSold2,036$33.33$67,860Form 4
May 4, 2026Yang LiExec. Vice President, ResearchSold1,584$33.33$52,795Form 4
Mar 24, 2026TCG Crossover Fund II L.P.10% ownerBought106,658$24.69$2.6 millionForm 4
Mar 23, 2026TCG Crossover Fund II L.P.10% ownerBought15,223$24.90$379,053Form 4
Mar 16, 2026TCG Crossover Fund II L.P.10% ownerBought1,190$24.99$29,738Form 4
Mar 13, 2026TCG Crossover Fund II L.P.10% ownerBought35,433$24.88$881,573Form 4
Mar 12, 2026TCG Crossover Fund II L.P.10% ownerBought12,374$24.99$309,226Form 4
Feb 12, 2026TCG Crossover Fund II L.P.10% ownerBought1,093$23.86$26,079Form 4
Feb 11, 2026TCG Crossover Fund II L.P.10% ownerBought17,763$23.58$418,852Form 4
Feb 3, 2026TCG Crossover GP III LLC10% ownerBought4,355$21.94$95,549Form 4
The latest 12 of 24 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40——−940.9%
Altman Z''−12.63−18.77−15.54
Accruals ratio−4.0%−97.2%−287.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't risePassFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Surrozen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
SurrozenFY25−67.4%−1,210.6%−873.5%———
CRISPR TherapeuticsFY25−90.6%−18,933.7%−9,855.5%———Compare
Dyadic InternationalFY25−11.6%−232.8%————Compare
CG OncologyFY25254.7%−4,722.1%−3,279.2%——2Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue—0120114
Revenue growth———−100.0%—−67.4%
Gross profit——————
Research and development264037272129
Operating income−33−54−44−46−26−42
Net income−33−55−36−43−64−242
Diluted EPS (US$)—−33.15−15.56−21.33−21.67−32.37
Diluted shares (millions)022238
Cash flow
Cash from operations−29−49−44−40−18−30
Capital expenditure111000
Free cash flow−30−50−45−41−18−30
Dividends paid000000
Share buybacks003000
Acquisitions000000
Stock-based compensation124444
Balance sheet at fiscal year end
Cash and short-term investments4912476363589
Debt incl. finance leases——————
Total assets6213789464899
Total liabilities152813870286
Shareholders' equity471107638−21−188
Margins and ratios
Gross margin——————
Operating margin——−354.7%—−239.7%−1,210.6%
Net margin——−288.0%—−596.6%−6,960.8%
Free cash flow margin——−359.0%—−165.7%−873.5%
Rule of 40 (growth + FCF margin)—————−940.9%
Return on capital——————
Return on equity—−69.6%−38.8%−75.5%−767.9%—
Return on assets—−54.9%−31.8%−63.5%−134.5%−328.9%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Surrozen's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Surrozen.